Information Provided By: 
Fly News Breaks for February 20, 2019
RDY, AQST
Feb 20, 2019 | 08:53 EDT
Lake Street analyst Thomas Flaten lowered his 2019 revenue estimate for Aquestive Therapeutics (AQST) to $43.5M from $67M after the Court of Appeals for the Federal Circuit issued its mandate yesterday, vacating the preliminary injunction that had barred Dr. Reddy's Laboratories (RDY) from entering the market. The analyst, however, believes any related downside has been more than priced into shares of Aquestive Therapeutics. He reiterates a Buy rating on the name and raised his price target for the stock to $17 from $14.
News For AQST;RDY From the Last 2 Days
There are no results for your query AQST;RDY
